ArticleScientific reports2023
Network pharmacology analysis reveals potential targets and mechanisms of proton pump inhibitors in breast cancer with diabetes.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Network Pharmacology Analysis of Glycyrrhetinic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2026Article
- Ethanol extract of Dysosma versipellis induces cytotoxicity in colonic epithelial cells via activation of the PI3K-Akt/MAPK signaling pathways.European journal of medical research · 2026Article
- METTL3-mediated mAnnals of medicine · 2025Article
- Integrating Chemo- and Bioinformatics withJournal of chemical information and modeling · 2025Article
- Identification of Novel Progesterone Receptor (PR) Inhibitors (Pharmaceuticals (Basel, Switzerland) · 2025Article
- Single-cell RNA seq data analysis reveals molecular markers and possible treatment targets for laryngeal squamous cell carcinoma (LSCC): an in-silico approach.In silico pharmacology · 2025Article
- Comparative Analysis of Multi-Omics Integration Using Graph Neural Networks for Cancer Classification.IEEE access : practical innovations, open solutions · 2025Article
- Article
- Unveiling the Bioactive Efficacy ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Multitarget Mechanisms of Monocarbonyl Curcuminoid Analogues against HL-60 Cancer Cells:ACS omega · 2024Article
- Article
- Molecular docking and network pharmacology study on active compounds ofIn silico pharmacology · 2024Article
- Unraveling the Therapeutic Mechanism ofNutrients · 2023Article
- Network pharmacology reveals the potential of Dolastatin 16 as a diabetic wound healing agent.In silico pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer and diabetes are significant health challenges, and effective treatments for both diseases are lacking. Proton pump inhibitors (PPIs) have demonstrated anticancer and hypoglycemic effects, but their mechanisms of action are not yet fully understood. We used the GeneCards and PharmMapper databases to identify therapeutic targets for diabetes, breast cancer and PPIs. We identified common targets and constructed a regulatory network of diseases and drugs using the STRING database and Cytoscape software. We also explored the binding between small molecule ligands and protein receptors using Discovery Studio software. We identified 33 shared targets for breast cancer, diabetes, and PPIs including lansoprazole, omeprazole, and pantoprazole, which play a critical role in fatty acid transport, insulin resistance, apoptosis, and cancer-related signaling pathways. Our findings demonstrated that PPIs had a strong affinity for AKT1 and MMP9. This study provides insights into the mechanisms of action of PPIs in breast cancer and diabetes and identifies AKT1 and MMP9 as critical targets for future drug development. Our findings highlight the potential of PPIs as a novel therapeutic approach for these challenging diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.